Altamira Therapeutics Ltd. (CYTOF)

Altamira Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0	1	0.73	0.02	1.08	12.73
Cash & Short-Term Investments	0	1	0.73	0.02	1.08	12.73
Cash Growth	-94.26%	36.11%	4309.00%	-98.46%	-91.52%	790.04%
Accounts Receivable	-	-	-	0.01	0.02	-
Other Receivables	0.21	0.35	0.09	0.82	0.73	0.07
Receivables	0.21	0.35	0.09	0.82	0.75	0.07
Inventory	-	-	-	0.01	0.92	-
Prepaid Expenses	0.03	0	0.08	0.77	0.15	0.12
Other Current Assets	-	0.19	0.55	0.29	1.59	0.21
Total Current Assets	0.25	1.54	1.45	1.91	4.49	13.13
Property, Plant & Equipment	0.43	0.45	0.1	0.48	0.62	0.05
Long-Term Investments	1.82	2.03	2.97	0.21	0.22	-
Other Intangible Assets	4.63	4.63	4.63	4.21	15.7	10.3
Total Assets	7.13	8.65	9.14	6.81	21.03	23.51

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Accounts Payable	0.76	0.52	0.49	5.31	3.89	0.82
Accrued Expenses	0.9	0.49	0.41	2.14	1.15	1.62
Short-Term Debt	0.45	-	-	6.35	-	0.59
Current Portion of Leases	0.15	0.12	0.12	0.13	0.13	-
Other Current Liabilities	0.05	0.03	0.03	-	0.17	0.4
Total Current Liabilities	2.31	1.16	1.06	13.92	5.33	3.42
Long-Term Leases	0.2	0.24	-	0.37	0.51	-
Long-Term Unearned Revenue	-	-	-	1.01	-	-
Pension & Post-Retirement Benefits	0.55	0.68	0.41	0.36	0.73	0.98
Long-Term Deferred Tax Liabilities	-	-	-	0.14	0.16	0.14
Other Long-Term Liabilities	-	-	-	-	0	0.01
Total Liabilities	3.06	2.09	1.47	15.8	6.73	4.55

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Common Stock	0.01	0.01	0	0.27	0.16	0.13
Additional Paid-In Capital	-	-	23.89	216.92	206.79	200.32
Retained Earnings	-4.04	-3.03	-21.35	-226.26	-192.72	-181.56
Comprehensive Income & Other	8.1	9.59	5.13	0.08	0.07	0.07
Shareholders' Equity	4.07	6.57	7.68	-8.99	14.3	18.95
Total Liabilities & Equity	7.13	8.65	9.14	6.81	21.03	23.51

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Total Debt	0.79	0.36	0.12	6.84	0.63	0.59
Net Cash (Debt)	-0.79	0.64	0.62	-6.83	0.45	12.13
Net Cash Growth	-	3.62%	-	-	-96.31%	748.62%
Net Cash Per Share	-0.18	0.23	1.25	-149.93	13.53	807.00
Filing Date Shares Outstanding	5.72	4.66	2.24	0.35	0.04	0.03
Total Common Shares Outstanding	5.72	4.66	1.48	0.06	0.04	0.03
Working Capital	-2.06	0.38	0.4	-12.01	-0.84	9.71
Book Value Per Share	0.71	1.41	5.19	-152.33	382.25	664.06
Tangible Book Value	-0.55	1.94	3.05	-13.2	-1.4	8.65
Tangible Book Value Per Share	-0.10	0.42	2.06	-223.67	-37.49	303.11
Machinery	-	0.75	0.59	0.59	0.64	0.66

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 12, 2026

Data Sources Report a data error